Treatment of Bevacizumab-Induced Glossitis and Proctitis
Discontinue bevacizumab immediately and initiate supportive care with topical mesalamine for proctitis and symptomatic management for glossitis, as bevacizumab-induced mucosal toxicities are likely mediated by VEGF inhibition disrupting normal mucosal repair mechanisms.
Understanding the Problem
Bevacizumab-induced glossitis and proctitis represent uncommon but clinically significant mucosal toxicities. While the FDA label for bevacizumab 1 does not specifically list glossitis or proctitis as labeled adverse events, emerging case reports document these complications. The mechanism likely involves VEGF inhibition disrupting normal angiogenesis required for mucosal healing and maintenance 2, 3.
Immediate Management Algorithm
For Glossitis:
Step 1: Discontinue bevacizumab
- Case reports demonstrate reversibility of oral mucosal lesions after bevacizumab discontinuation 2, 3, 4
- One case series showed characteristic erythematous erosions on the tongue that resolved after stopping therapy 3
- Vocal fold necrosis cases showed complete resolution 11-24 months after discontinuation 4
Step 2: Symptomatic relief
- Avoid spicy, acidic, or irritating foods (increased sensitivity commonly reported 3)
- Consider topical analgesics for severe pain
- Maintain excellent oral hygiene to prevent secondary infection
- Polaprezinc has been used in Japanese case series for bevacizumab-associated oral mucositis 5
Step 3: Monitor for secondary complications
- Assess for fungal superinfection (reported in 6/11 patients in one series 5)
- Treat candidiasis if present with topical or systemic antifungals
- Evaluate periodontal disease and dental caries as contributing factors 5
For Proctitis:
Step 1: Discontinue bevacizumab
- Bevacizumab can cause ischemic colitis that may progress to perforation 6
- Early recognition and drug discontinuation is critical
Step 2: Apply ulcerative colitis proctitis treatment principles
While the provided guidelines 7, 8, 9 address infectious and inflammatory proctitis rather than drug-induced proctitis, the treatment approach for mucosal inflammation can be adapted:
- Topical mesalamine 1g suppositories daily 8, 9 - This is the preferred first-line therapy for proctitis and may help with mucosal healing
- Mesalamine suppositories deliver medication directly to the rectum and are better tolerated than enemas 8
Step 3: Supportive care
- For radiation-induced proctitis (similar pathophysiology of vascular injury), sucralfate enemas are suggested for rectal bleeding 10, 11
- This may be applicable to bevacizumab-induced proctitis given the shared mechanism of vascular disruption
- Monitor for progression to ischemic colitis requiring surgical intervention 6
Critical Pitfalls to Avoid
Do not continue bevacizumab - Unlike chemotherapy-induced mucositis where treatment often continues, bevacizumab-induced mucosal toxicity requires drug discontinuation for resolution 2, 4
Do not assume infectious etiology alone - While the CDC guidelines 12 focus on sexually transmitted proctitis (gonorrhea, chlamydia, HSV), bevacizumab-induced proctitis has a vascular/ischemic mechanism requiring different management
Watch for rapid progression - Bevacizumab-associated ischemic colitis can progress to perforation requiring emergency surgery 6. One case report described severe ischemic pancolitis that fortunately responded to conservative management, but surgical readiness is essential
Consider pre-existing risk factors - Patients with diabetes, poor oral hygiene, periodontal disease, or smoking have higher risk for severe oral mucositis 5
Prognosis and Recovery
- Glossitis typically improves within weeks to months after bevacizumab discontinuation 3, 4
- Some patients may have persistent mild changes (shallow sulci, mild breathiness in vocal fold cases) 4
- Proctitis recovery depends on severity; ischemic changes may resolve with conservative management if caught early 6
When to Escalate Care
- For glossitis: Inability to maintain oral intake, signs of systemic infection, or no improvement 2-4 weeks after discontinuation
- For proctitis: Severe abdominal pain, peritoneal signs, fever, or bloody diarrhea suggesting progression to ischemic colitis or perforation requiring immediate surgical consultation 6